BB1001 lead program
Dysregulated transcription is implicated in many diseases, including cancer. Bluedot Bio has developed a first-in-class transcription modulator, the cyclic decoy, to block disease progression. Our first drug, BB1001, targets Signal Transducer Activator Transcription 3 (STAT3), an oncogenic transcription factor commonly overexpressed in many cancer types.
- Scientific validation: Two decades of research conducted with in vitro, animals, and cancer patients
- Multiple STAT3 diseases: BB1001 can be used in all STAT3 overexpressed diseases, including cancer, some rare genetic disorders, psoriasis, and inflammatory conditions
- Additional decoy development: Bluedot Bio is developing additional decoys for other dysregulated transcription factors
Play Video
Our portfolio of companies
CAR-T platform
Pioneering differentiated cell-based therapies to treat solid tumors
AI technology
Harnessing drug discovery in motion with the full power of next generation computer aided drug design to bring novel small molecule drugs to the clinic
Novel antibody technology
A new antibody to treat gastrointestinal cancers that is rapidly moving to the clinic